<DOC>
	<DOCNO>NCT01909453</DOCNO>
	<brief_summary>This 2-part , randomize , open label , multi-center , parallel group , phase III study compare efficacy safety LGX818 plus MEK162 vemurafenib LGX818 monotherapy patient locally advance unresectable metastatic melanoma BRAF V600 mutation . A total approximately 900 patient randomize . Part 1 : Patients randomize 1:1:1 ratio one 3 treatment arm : 1 . LGX818 450 mg QD plus MEK162 45 mg BID ( denote Combo 450 arm ) 2 . LGX818 300 mg QD monotherapy ( denote LGX818 arm ) 3. vemurafenib 960 mg BID ( denote vemurafenib arm ) Part 2 : Patients randomize 3:1 ratio one 2 treatment arm : 1 . LGX818 300 mg QD plus MEK162 45 mg BID ( denote Combo 300 arm ) 2 . LGX818 300 mg QD monotherapy ( denote LGX818 arm )</brief_summary>
	<brief_title>Study Comparing Combination LGX818 Plus MEK162 Versus Vemurafenib LGX818 Monotherapy BRAF Mutant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Diagnosis locally advance , unresectable metastatic cutaneous melanoma unknown primary melanoma ( AJCC Stage IIIB , IIIC , IV ) Presence BRAF V600E V600K mutation tumor tissue prior randomization Na√Øve untreated patient patient progress prior first line immunotherapy resectable locally advanced metastatic melanoma ; prior adjuvant therapy permit ( e.g . IFN , IL2 therapy , immunotherapy , radiotherapy chemotherapy ) , except administration BRAF MEK inhibitor Evidence least one measurable lesion detect radiological photographic method ECOG performance status 0 1 Adequate bone marrow , organ function , cardiac laboratory parameter Normal function daily living activity Any untreated central nervous system ( CNS ) lesion Uveal mucosal melanoma History leptomeningeal metastases History current evidence central serous retinopathy ( CSR ) , retinal vein occlusion ( RVO ) history retinal degenerative disease Any previous systemic chemotherapy treatment , extensive radiotherapy investigational agent immunotherapy , patient receive one line immunotherapy locally advance unresectable metastatic melanoma ; Ipilimumab ( adjuvant ) immunotherapy treatment must end least 6 week prior randomization History Gilbert 's syndrome Prior therapy BRAF inhibitor and/or MEK inhibitor Impaired cardiovascular function clinically significant cardiovascular disease Uncontrolled arterial hypertension despite medical treatment HIV positive active Hepatitis B , and/or active Hepatitis C Impairment gastrointestinal function Patients neuromuscular disorder associate elevated CK Pregnant nursing ( lactate ) woman Medical , psychiatric , cognitive condition may compromise patient 's ability understand patient information , give informed consent , comply study protocol complete study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Cutaneous melanoma</keyword>
	<keyword>Skin disease</keyword>
	<keyword>Skin cancer</keyword>
	<keyword>Skin Neoplasms</keyword>
	<keyword>Neoplasm Metastasis</keyword>
	<keyword>BRAF mutant</keyword>
	<keyword>BRAF V600E</keyword>
	<keyword>BRAF V600K</keyword>
	<keyword>Cancer</keyword>
	<keyword>LGX818</keyword>
	<keyword>MEK162</keyword>
	<keyword>vemurafenib</keyword>
	<keyword>combination</keyword>
	<keyword>BRAF inhibitor</keyword>
	<keyword>resistance</keyword>
	<keyword>The combination selective BRAF- MEK1/2-inhibitor</keyword>
	<keyword>Prior immunotherapy</keyword>
	<keyword>MEK inhibitor</keyword>
	<keyword>Phase III</keyword>
	<keyword>Combo 300 , Combo 450</keyword>
</DOC>